ABSTRACT
Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Bleomycin , Brentuximab Vedotin , Dacarbazine , Doxorubicin , Hodgkin Disease , Positron-Emission Tomography , Vinblastine , Humans , Hodgkin Disease/drug therapy , Hodgkin Disease/diagnostic imaging , Hodgkin Disease/therapy , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Brentuximab Vedotin/therapeutic use , Male , Female , Adult , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Middle Aged , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Vinblastine/therapeutic use , Vinblastine/administration & dosage , Dacarbazine/therapeutic use , Dacarbazine/administration & dosage , Young Adult , Neoplasm Staging , Aged , Treatment Outcome , Follow-Up StudiesABSTRACT
Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.
Subject(s)
Antineoplastic Agents , Bleomycin , Carboplatin , Carcinoma, Squamous Cell , Cat Diseases , Electrochemotherapy , Skin Neoplasms , Animals , Cats , Electrochemotherapy/veterinary , Electrochemotherapy/methods , Bleomycin/therapeutic use , Bleomycin/administration & dosage , Skin Neoplasms/veterinary , Skin Neoplasms/drug therapy , Cat Diseases/drug therapy , Carboplatin/therapeutic use , Carboplatin/administration & dosage , Female , Male , Carcinoma, Squamous Cell/veterinary , Carcinoma, Squamous Cell/drug therapy , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/administration & dosage , Prospective Studies , Treatment OutcomeABSTRACT
Ranula is a mucous cyst that occurs in the sublingual gland (SLG) in the floor of the mouth. It can be classified into two types based on origins: One is the the lesser sublingual gland (LSLG) in the anterior segment and the Rivini duct, which is connected to it, and the other is the greater sublingual gland (GSLG) in the posterior segment. Because of the anatomical characteristics, surgical resection of the cysts carries the risk of damaging adjacent tissues and has a high recurrence rate. Intralesional injection of sclerotherapy may be a better alternative treatment. We summarized 65 cases of ranula treated with intralesional injections of bleomycin(BML). According to the origin of the ranula, 60 cases were from the LSLG and the Rivini duct, and 5 cases were from the GSLG. The results showed that 60 cases of ranula from LSLG and Rivini ducts were 100% cured during the follow-up period. The median number of injections for all patients was 1.16. All 5 cases of ranula from the GSLG did not wholly recover. This study confirmed that BLM intralesional injection is a safe and effective treatment modality for cysts from LSLG or the ducts of Rivini rather than GSLG. Therefore, before treatment, it is necessary to determine the type and origin of the cyst by characterizing its morphology to ensure the effectiveness of the treatment.
Subject(s)
Bleomycin , Injections, Intralesional , Ranula , Sclerotherapy , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Humans , Sclerotherapy/methods , Female , Adult , Male , Middle Aged , Adolescent , Sclerosing Solutions/therapeutic use , Sclerosing Solutions/administration & dosage , Young Adult , Treatment Outcome , Aged , Child , Sublingual GlandABSTRACT
Electrochemotherapy (ECT) combines the reversible electroporation (rEP) with intravenous (i.v.) or intratumoral (i.t.) administration of chemotherapeutic drugs. We conducted this study to compare the efficacy of i.v., i.t., and i.v. + i.t. injection of bleomycin (BLM) in ECT treatment of colorectal hepatic metastases in a rat model. WAG/Rij rats were randomized into three groups and underwent ECT with i.v., i.t., or i.v. + i.t. injection of BLM. Tumor volumes and oxygenation were measured by means of ultrasound and photoacoustic imaging. Moreover, liver and tumor tissue were analyzed by histology and immunohistochemistry. The i.v. and i.v. + i.t. groups exhibited a 44.0% and 46.6% reduction in oxygen saturation of the tumor tissue when compared to pretreatment values, whereas the i.t. group only showed a reduction of 35.2%. The extent of tumor tissue necrosis did not statistically differ between the groups. However, the i.t. group showed a tendency towards a lower necrosis rate. Cell proliferation, apoptotic cell death, vascularization, and immune cell infiltration were comparable in the treated tumors of the three groups. ECT with i.v. administration of BLM should be preferred in clinical practice, as the combined i.v. + i.t. therapy did not show superior oncological outcomes in the present study.
Subject(s)
Bleomycin , Colorectal Neoplasms , Electrochemotherapy , Liver Neoplasms , Animals , Bleomycin/administration & dosage , Electrochemotherapy/methods , Colorectal Neoplasms/pathology , Colorectal Neoplasms/drug therapy , Rats , Liver Neoplasms/secondary , Liver Neoplasms/drug therapy , Disease Models, Animal , Antibiotics, Antineoplastic/administration & dosage , Male , Administration, Intravenous , Combined Modality Therapy , Injections, IntralesionalABSTRACT
INTRODUCTION: Trophoblastic neoplasms are often associated with pregnancy, and nongestational trophoblastic neoplasms are extremely rare. Nongestational ovarian choriocarcinoma (NGCO) is a highly aggressive germ cell-derived tumor frequently presenting with early hematogenous metastasis. PATIENT CONCERNS: Herein, we report a case of a 28-year-old unmarried woman with regular menstruation who experienced vaginal bleeding 1 week after her last menstrual cycle. Doppler ultrasound revealed bilateral adnexal masses and elevated serum human chorionic gonadotropin (hCG) levels. The patient was initially misdiagnosed as presenting an ectopic pregnancy. DIAGNOSIS: The final pathology confirmed an International Federation of Gynecology and Obstetrics stage IA NGCO with bilateral mature teratoma of the ovary. This is an extraordinary instance of ovarian choriocarcinoma which emerged without any prior gestation, and the patient's lack of a history of pregnancy made the diagnosis ignored. INTERVENTIONS: After initial surgery and 1 cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, a laparoscopic fertility-preserving comprehensive staging surgery was performed. Two cycles of chemotherapy with BEP were administered as supplemental therapy postsurgery, and leuprorelin was administered to protect ovarian function. OUTCOMES: Menstruation resumed 4 months after chemotherapy completion, and tumor indicators were within the normal range. No signs of recurrence were observed at the 36-month follow-up. CONCLUSION: NGCO should be considered if a female patient exhibits irregular vaginal bleeding and masses in the adnexal area. The present case and our literature review also highlighted that fertility-sparing surgery and multidrug chemotherapy are effective methods for treating NGCO.
Subject(s)
Choriocarcinoma, Non-gestational , Ovarian Neoplasms , Teratoma , Humans , Female , Adult , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Teratoma/diagnosis , Teratoma/pathology , Choriocarcinoma, Non-gestational/diagnosis , Choriocarcinoma, Non-gestational/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Etoposide/therapeutic use , Etoposide/administration & dosage , Pregnancy , Bleomycin/administration & dosage , Bleomycin/therapeutic useABSTRACT
Since phospholipids have an important effect on the size, surface potential and hardness of liposomes that decide their in vivo fate after inhalation, this research has systematically evaluated the effect of phospholipids on pulmonary drug delivery by liposomes. In this study, liposomes composed of neutral saturated/unsaturated phospholipids, anionic and cationic phospholipids were constructed to investigate how surface potential and the degree of saturation of fatty acid chains determined their mucus and epithelium permeability both in vitro and in vivo. Our results clearly indicated that liposomes composed of saturated neutral and anionic phospholipids possessed high stability and permeability, compared to that of liposomes composed of unsaturated phospholipids and cationic phospholipids. Furthermore, both in vivo imaging of fluorescence-labeled liposomes and biodistribution of salvianolic acid B (SAB) that encapsulated in liposomes were performed to estimate the effect of phospholipids on the lung exposure and retention of inhaled liposomes. Finally, inhaled SAB-loaded liposomes exhibited enhanced therapeutic effects in a bleomycin-induced idiopathic pulmonary fibrosis mice model via inhibition of inflammation and regulation on coagulation-fibrinolytic system. Such findings will be beneficial to the development of inhalable lipid-based nanodrug delivery systems for the treatment of respiratory diseases where inhalation is the preferred route of administration.
Subject(s)
Benzofurans , Idiopathic Pulmonary Fibrosis , Liposomes , Mice, Inbred C57BL , Phospholipids , Animals , Benzofurans/administration & dosage , Benzofurans/pharmacokinetics , Idiopathic Pulmonary Fibrosis/drug therapy , Phospholipids/chemistry , Phospholipids/administration & dosage , Administration, Inhalation , Lung/metabolism , Lung/drug effects , Male , Tissue Distribution , Bleomycin/administration & dosage , Mice , Humans , DepsidesABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a high mortality rate due to limited treatment options. Current therapies cannot effectively reverse the damage caused by IPF. Research suggests that promoting programmed cell death (apoptosis) in myofibroblasts, the key cells driving fibrosis, could be a promising strategy. However, inducing apoptosis in healthy cells like epithelial and endothelial cells can cause unwanted side effects. This project addresses this challenge by developing a targeted approach to induce apoptosis specifically in myofibroblasts. We designed liposomes (LPS) decorated with peptides that recognize VCAM-1, a protein highly expressed on myofibroblasts in fibrotic lungs. These VCAM1-targeted LPS encapsulate Venetoclax (VNT), a small molecule drug that inhibits BCL-2, an anti-apoptotic protein. By delivering VNT directly to myofibroblasts, we hypothesize that VCAM1-VNT-LPS can selectively induce apoptosis in these cells, leading to reduced fibrosis and improved lung function. We successfully characterized VCAM1-VNT-LPS for size, surface charge, and drug loading efficiency. Additionally, we evaluated their stability over three months at different temperatures. In vitro and in vivo studies using a bleomycin-induced mouse model of lung fibrosis demonstrated the therapeutic potential of VCAM1-VNT-LPS. These studies showed a reduction in fibrosis-associated proteins (collagen, α-SMA, VCAM1) and BCL-2, while simultaneously increasing apoptosis in myofibroblasts. These findings suggest that VCAM1-targeted delivery of BCL-2 inhibitors using liposomes presents a promising and potentially selective therapeutic approach for IPF.
Subject(s)
Apoptosis , Bridged Bicyclo Compounds, Heterocyclic , Liposomes , Mice, Inbred C57BL , Nanoparticles , Proto-Oncogene Proteins c-bcl-2 , Sulfonamides , Vascular Cell Adhesion Molecule-1 , Animals , Proto-Oncogene Proteins c-bcl-2/metabolism , Nanoparticles/administration & dosage , Sulfonamides/administration & dosage , Sulfonamides/pharmacology , Sulfonamides/therapeutic use , Vascular Cell Adhesion Molecule-1/metabolism , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Apoptosis/drug effects , Myofibroblasts/drug effects , Myofibroblasts/metabolism , Humans , Lung/pathology , Lung/drug effects , Lung/metabolism , Idiopathic Pulmonary Fibrosis/drug therapy , Idiopathic Pulmonary Fibrosis/pathology , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/pathology , Male , Mice , Bleomycin/administration & dosageABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and life-threatening lung disease for which treatment options are limited. Glycyrrhetinic acid (GA) is a triterpenoid with multiple biological effects, such as anti-inflammatory and anti-fibrotic properties. Herein, inhalable milk-derived extracellular vesicles (mEVs) encapsulating GA (mEVs@GA) were screened and evaluated for IPF treatment. The results indicated that the loading efficiency of GA in mEVs@GA was 8.65%. Therapeutic effects of inhalable mEVs@GA were investigated in vitro and in vivo. The mEVs@GA demonstrated superior anti-inflammatory effects on LPS-stimulated MHS cells. Furthermore, repeated noninvasive inhalation delivery of mEVs@GA in bleomycin-induced IPF mice could decrease the levels of transforming growth factors ß1 (TGF-ß1), Smad3 and inflammatory cytokines IL-6, IL-1ß and TNF-α. The mEVs@GA effectively diminished the development of fibrosis and improved pulmonary function in the IPF mice model at a quarter of the dose compared with the pirfenidone oral administration group. Additionally, compared to pirfenidone-loaded mEVs, mEVs@GA demonstrated superior efficacy at the same drug concentration in the pharmacodynamic study. Overall, inhaled mEVs@GA have the potential to serve as an effective therapeutic option in the treatment of IPF.
Subject(s)
Cytokines , Extracellular Vesicles , Glycyrrhetinic Acid , Idiopathic Pulmonary Fibrosis , Mice, Inbred C57BL , Milk , Animals , Glycyrrhetinic Acid/administration & dosage , Idiopathic Pulmonary Fibrosis/drug therapy , Idiopathic Pulmonary Fibrosis/chemically induced , Administration, Inhalation , Milk/chemistry , Cytokines/metabolism , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Bleomycin/administration & dosage , Male , Lung/metabolism , Lung/drug effects , Mice , Humans , Cell Line , Drug Carriers/chemistry , Drug Carriers/administration & dosage , Smad3 Protein/metabolismABSTRACT
Vanishing bile duct syndrome is an uncommon condition characterised by the progressive loss and disappearance of bile ducts. It is an acquired form of cholestatic liver disease presenting with hepatic ductopenia (loss of >50% bile ducts in the portal areas). We present a case of vanishing bile duct syndrome as a presentation of Hodgkin's lymphoma who was treated with standard-of-care chemotherapy-doxorubicin, bleomycin, vinblastine and dacarbazine (along with brief administration of rituximab), which led to complete response and normalisation of liver function.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Bleomycin , Hodgkin Disease , Adult , Female , Humans , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bile Duct Diseases/diagnosis , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Dacarbazine/therapeutic use , Dacarbazine/administration & dosage , Doxorubicin/therapeutic use , Hodgkin Disease/complications , Hodgkin Disease/drug therapy , Hodgkin Disease/diagnosis , Rituximab/therapeutic use , Rituximab/administration & dosage , Syndrome , Vinblastine/therapeutic use , Vinblastine/administration & dosageABSTRACT
Continuous and aberrant activation of myofibroblasts is the hallmark of pathological fibrosis (e.g., abnormal wound healing). The deposition of excessive extracellular matrix (ECM) components alters or increases the stiffness of tissue and primarily accounts for multiple organ dysfunctions. Among various proteins, Cadherin-11 (CDH11) has been reported to be overexpressed on myofibroblasts in fibrotic tissues. Anti-apoptotic proteins such as (B cell lymphoma-2) (BCL-2) are also upregulated on myofibroblasts. Therefore, we hypothesize that CDH11 could be a targeted domain for cell-specific drug delivery and targeted inhibition of BCL-2 to ameliorate the development of fibrosis in the skin. To prove our hypothesis, we have developed liposomes (LPS) conjugated with CDH11 neutralizing antibody (antiCDH11) to target cell surface CDH11 and loaded these LPS with a BCL-2 inhibitor, Navitoclax (NAVI), to induce apoptosis of CDH11 expressing fibroblasts. The developed LPS were evaluated for physicochemical characterization, stability, in vitro therapeutic efficacy using dermal fibroblasts, and in vivo therapeutic efficacy in bleomycin-induced skin fibrosis model in mice. The findings from in vitro and in vivo studies confirmed that selectivity of LPS was improved towards CDH11 expressing myofibroblasts, thereby improving therapeutic efficacy with no indication of adverse effects. Hence, this novel research work represents a versatile LPS strategy that exhibits promising potential for treating skin fibrosis.
Subject(s)
Apoptosis , Cadherins , Fibrosis , Liposomes , Skin , Animals , Apoptosis/drug effects , Fibrosis/drug therapy , Cadherins/metabolism , Skin/pathology , Skin/drug effects , Skin/metabolism , Humans , Fibroblasts/drug effects , Fibroblasts/metabolism , Aniline Compounds/administration & dosage , Aniline Compounds/pharmacology , Aniline Compounds/therapeutic use , Aniline Compounds/chemistry , Sulfonamides/administration & dosage , Sulfonamides/pharmacology , Sulfonamides/therapeutic use , Bleomycin/administration & dosage , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Mice, Inbred C57BL , Antibodies, Neutralizing/administration & dosage , Antibodies, Neutralizing/therapeutic use , Mice , MaleABSTRACT
Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment-naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real-life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real-life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty-one patients were enrolled (62% had advanced stage). iPET2 was positive in 89 patients (14%) including 8.7% and 17% early and advanced stage patients, respectively (p = 0.003). Among iPET 2 positive cases treatment was immediately modified in 19 cases; in 14 cases treatment was modified after an additional positive iPET4. Overall 56 iPET2 positive patients never received intensified therapies. Most frequently used intensified therapy was autologous stem cell transplantation followed by BEACOPP. After a median follow-up of 72 months, the 5-year progression-free survival (PFS) was 82% with iPET2 positive patients showing a worse PFS compared with iPET2 negative cases: 31% versus 85%. Focusing on advanced stage patients with a positive iPET2, the 5-year PFS was 59% for patients shifted to intensified therapy at any time point versus 61% for patients who never received intensified therapy. Our study confirmed the higher curability of naïve cHL patients in a real-world setting, and the prognostic role of iPET2 in this setting. A poor adherence to response-adapted strategy which however did not translate into a difference in patient outcomes.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Hodgkin Disease , Humans , Hodgkin Disease/therapy , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Hodgkin Disease/mortality , Male , Female , Adult , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Retrospective Studies , Adolescent , Young Adult , Aged , Prognosis , Positron-Emission Tomography , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Etoposide/administration & dosage , Vincristine/administration & dosage , Vincristine/therapeutic use , Prednisone/administration & dosage , Prednisone/therapeutic use , Procarbazine/administration & dosage , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Survival Rate , Cyclophosphamide/administration & dosage , Cyclophosphamide/therapeutic use , Follow-Up StudiesABSTRACT
Systemic sclerosis (SSc) with interstitial lung disease (SSc-ILD) lacks curative pharmacological treatments, thus necessitating effective animal models for candidate drug discovery. Existing bleomycin (BLM)-induced SSc-ILD mouse models feature spatially limited pulmonary fibrosis, spontaneously resolving after 28 days. Here, we present an alternative BLM administration approach in female C57BL/6 mice, combining oropharyngeal aspiration (OA) and subcutaneous mini-pump delivery (pump) of BLM to induce a sustained and more persistent fibrosis, while retaining stable skin fibrosis. A dose-finding study was performed with BLM administered as 10 µg (OA) +80 mg/kg (pump) (10 + 80), 10 + 100, and 15 + 100. Forty-two days after OA, micro-computed tomography (micro-CT) imaging and histomorphometric analyses showed that the 10 + 100 and 15 + 100 treatments induced significant alterations in lung micro-CT-derived readouts, Ashcroft score, and more severe fibrosis grades compared with saline controls. In addition, a marked reduction in hypodermal thickness was observed in the 15 + 100 group. A time-course characterization of the BLM 15 + 100 treatment at days 28, 35, and 42, including longitudinal micro-CT imaging, revealed progressing alterations in lung parameters. Lung histology highlighted a sustained fibrosis accompanied by a reduction in hypodermis thickness throughout the explored time-window, with a time-dependent increase in fibrotic biomarkers detected by immunofluorescence analysis. BLM-induced alterations were partly mitigated by Nintedanib treatment. Our optimized BLM delivery approach leads to extensive and persistent lung fibrotic lesions coupled with cutaneous fibrotic alterations: it thus represents a significant advance compared with current preclinical models of BLM-induced SSc-ILD.NEW & NOTEWORTHY This study introduces an innovative approach to enhance the overall performance of the mouse bleomycin (BLM)-induced model for systemic sclerosis with interstitial lung disease (SSc-ILD). By combining oropharyngeal aspiration and subcutaneous mini-pump delivery of BLM, our improved model leads to sustained lung fibrosis and stable skin fibrosis in female C57BL/6 mice. The optimized 15 + 100 treatment results in extensive and persistent lung fibrotic lesions and thus represents a significant improvement over existing preclinical models of BLM-induced SSc-ILD.
Subject(s)
Bleomycin , Disease Models, Animal , Mice, Inbred C57BL , Pulmonary Fibrosis , Animals , Bleomycin/administration & dosage , Bleomycin/toxicity , Female , Pulmonary Fibrosis/pathology , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/drug therapy , Mice , Scleroderma, Systemic/pathology , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/complications , X-Ray Microtomography , Skin/pathology , Skin/drug effects , Lung/pathology , Lung/drug effects , Lung/diagnostic imaging , Oropharynx/pathology , Oropharynx/drug effects , Oropharynx/diagnostic imaging , Lung Diseases, Interstitial/pathology , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnostic imagingABSTRACT
Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin-containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population-based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age- and sex-matched comparators from the background population. Median follow-up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30-3.68]), with a 10-year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35-26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43-2.76]), with a 10-year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43-1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B-symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work-up of pulmonary symptoms.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Hodgkin Disease , Lung Diseases , Humans , Hodgkin Disease/epidemiology , Hodgkin Disease/drug therapy , Female , Male , Adult , Denmark/epidemiology , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Diseases/chemically induced , Lung Diseases/epidemiology , Lung Diseases/etiology , Aged , Bleomycin/adverse effects , Bleomycin/administration & dosage , Young Adult , Incidence , Procarbazine/adverse effects , Procarbazine/administration & dosage , Vincristine/adverse effects , Vincristine/therapeutic use , Vincristine/administration & dosage , Cohort Studies , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Cyclophosphamide/administration & dosage , Adolescent , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Doxorubicin/administration & dosageABSTRACT
Hemangiomas are most common benign liver tumor. Most patients have an excellent prognosis because of the small size and benign nature of tumor. On some occasions, giant liver hemangioma may cause symptoms and significant challenges due to its complication. We report a case of giant liver hemangioma treated with minimal invasive approach by transarterial embolization (TAE). Following three TAE sessions over a specific timeframe, the patient was successfully managed, addressing that TAE may be a useful alternative to hepatic surgery in such cases.
Subject(s)
Bleomycin , Embolization, Therapeutic , Ethiodized Oil , Hemangioma , Liver Neoplasms , Humans , Liver Neoplasms/therapy , Liver Neoplasms/diagnostic imaging , Hemangioma/therapy , Hemangioma/diagnostic imaging , Ethiodized Oil/administration & dosage , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Embolization, Therapeutic/methods , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/therapeutic use , Female , Male , Middle Aged , Emulsions , Chemoembolization, Therapeutic/methodsABSTRACT
BACKGROUND: Sclerotherapy is purportedly less effective in patients with hemorrhagic than with non-hemorrhagic lymphatic malformations (LMs). We aimed to compare the efficacy of bleomycin-lauromacrogol foam (BLF) sclerotherapy in the treatment of macrocystic LMs with and without intralesional hemorrhage. METHODS: Fifty-five children with macrocystic LMs admitted to the Pediatric Surgery Department were retrospectively included. The patients were allocated into a hemorrhage group (23 cases) or a non-hemorrhage group (32 cases) based on the occurrence of an intracapsular hemorrhage. The diagnosis was confirmed by physical examination, color ultrasound, magnetic resonance imaging, and puncture findings. BLF was injected into the capsule after draining the cystic fluid under color ultrasound guidance. Patients whose lesions were unchanged or showed minor change after 1 month were treated again using the same method. Changes in lesion size and the number of treatments were recorded. Effectiveness was classified as excellent (volume reduction ≥90%), good (50%≤volume reduction<90%), or poor (volume reduction <50%). RESULTS: In the hemorrhage group, 17, 6, and 0 patients' outcomes were classified as excellent, good, and poor, respectively. The overall efficacy rate was 100%. In the non-hemorrhage group, 23, 7, and 2 patients' outcomes were classified as excellent, good, and poor, respectively. The overall efficacy rate was 93.8%. There was no significant difference in efficacy rate between groups (P = 0.767). CONCLUSIONS: BLF is an effective and safe treatment for macrocystic LMs with bleeding. The results were similar in patients with and without bleeding. LEVEL OF EVIDENCE: Treatment, Level III.
Subject(s)
Bleomycin , Hemorrhage , Lymphatic Abnormalities , Sclerosing Solutions , Sclerotherapy , Humans , Sclerotherapy/methods , Male , Female , Retrospective Studies , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Lymphatic Abnormalities/drug therapy , Lymphatic Abnormalities/therapy , Child, Preschool , Hemorrhage/etiology , Child , Sclerosing Solutions/administration & dosage , Sclerosing Solutions/therapeutic use , Infant , Treatment Outcome , Polidocanol/administration & dosage , Polidocanol/therapeutic use , Adolescent , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/therapeutic useABSTRACT
BACKGROUND: Plantar warts are common infectious cutaneous growths causing severe physiological and psychological discomforts in patients and heaving global financial burdens. However, paucity of clear-cut guidelines for plantar warts, selecting appropriate treatments for plantar warts remains challenging. The objective of the study is to evaluate the efficacy and safety of common treatments for plantar warts. METHODS: PubMed, EMbase, and The Cochrane Library were searched from inception to March 1, 2023 for randomized controlled trials (RCTs) of plantar warts. The primary outcome (complete response) and secondary outcome (recurrence and pain) were extracted and combined using Bayesian network meta-analysis (NMA) with random-effect and fixed-effect models. RESULTS: Totally, 33 RCTs were included in the systematic review and quantitative NMA. In NMA of complete response, topical application of 1% cantharidin, 20% podophylotoxin, 30% salicylic acid (CPS), microneedles plus bleomycin (MNB), and intralesional bleomycin injection (INB) were the only three treatments significantly superior to no treatment (NT) and CPS was of the highest possibility to be the top-ranked treatment (SUCRA = 0.9363). However, traditional warts treatments, salicylic acid (SA) and cryotherapy were not superior to NT. CONCLUSIONS: The NMA has produced evidence for using CPS, MNB, and INB, which are all topical antimitotic treatments, to improve the management of plantar warts. The classic treatment modalities for plantar warts, including SA and cryotherapy, may play a less important role in the clinical practice of plantar warts.
Subject(s)
Bayes Theorem , Network Meta-Analysis , Randomized Controlled Trials as Topic , Warts , Humans , Warts/drug therapy , Antimitotic Agents/therapeutic use , Antimitotic Agents/administration & dosage , Salicylic Acid/therapeutic use , Salicylic Acid/administration & dosage , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Podophyllotoxin/therapeutic use , Podophyllotoxin/administration & dosage , Cantharidin/therapeutic use , Cantharidin/administration & dosage , Administration, TopicalABSTRACT
Background and purpose To predict treatment-related cardiovascular disease (CVD) and second cancer 30-yea. absolute mortality risks (AMR30) for patients with mediastinal Hodgkin lymphoma in a large multicentre radiation oncology network in Ireland. Material and methods This study includes consecutive patients treated for mediastinal lymphoma using chemotherapy and involved site radiotherapy (RT) 20162019. Radiation doses to heart, left ventricle, cardiac valves, lungs, oesophagus, carotid arteries and female breasts were calculated. Individual CVD and second cancer AMR30 were predicted using Irish background population rates and doseresponse relationships. Results Forty-four patients with Hodgkin lymphoma were identified, 23 females, median age 28 years. Ninety-eight percent received anthracycline, 80% received 46 cycles ABVD. Volumetric modulated arc therapy (VMAT) ± deep inspiration breath hold (DIBH) was delivered, median total prescribed dose 30 Gy. Average mean heart dose 9.8 Gy (range 0.223.8 Gy). Excess treatment-related mean AMR30 from CVD was 2.18% (0.79, 0.90, 0.01, 0.13 and 0.35% for coronary disease, heart failure, valvular disease, stroke and other cardiac diseases), 1.07% due to chemotherapy and a further 1.11% from RT. Excess mean AMR30 for second cancers following RT were: lung cancer 2.20%, breast cancer in females 0.34%, and oesophageal cancer 0.28%. Conclusion For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects (AU)
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Mediastinal Neoplasms/etiology , Mediastinal Neoplasms/radiotherapy , Neoplasms, Second Primary , Radiotherapy, Intensity-Modulated , Antineoplastic Combined Chemotherapy Protocols , Bleomycin/administration & dosage , Dacarbazine/administration & dosage , Radiotherapy Dosage , Vinblastine/administration & dosageSubject(s)
Humans , Keratoacanthoma/drug therapy , Injections, Intralesional , Administration, Topical , Methotrexate/administration & dosage , Imiquimod/administration & dosage , Fluorouracil/administration & dosage , Bleomycin/administration & dosage , Adrenal Cortex Hormones/administration & dosage , Interferon-alpha/administration & dosageSubject(s)
Humans , Keratoacanthoma/drug therapy , Injections, Intralesional , Administration, Topical , Methotrexate/administration & dosage , Imiquimod/administration & dosage , Fluorouracil/administration & dosage , Bleomycin/administration & dosage , Adrenal Cortex Hormones/administration & dosage , Interferon-alpha/administration & dosageABSTRACT
No disponible